Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study ...

Last week, Australia ’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, ...

Now, a study ... in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study ...